Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas

Abstract

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.20.00444 JCO Precision Oncology no. 5 (2021) 876-883. Published online May 20, 2021. Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas Sameer Farouk Sait , MBBS1,2xSameer Farouk SaitSearch for articles by this author; Stephen W. Gilheeney, MD, MMS1,2xStephen W. GilheeneySearch for articles by this author; Tejus A. Bale , MD, PhD3xTejus A. BaleSearch for articles by this author; Sofia Haque , MD4xSofia HaqueSearch for articles by this author; Marc J. Dinkin , MD5xMarc J. DinkinSearch for articles by this author; Stephanie Vitolano , MS1xStephanie VitolanoSearch for articles by this author; Marc K. Rosenblum , MD3xMarc K. RosenblumSearch for articles by this author; Katarzyna Ibanez , MD6xKatarzyna IbanezSearch for articles by this author; Daniel E. Prince , MD, MPH7xDaniel E. PrinceSearch for articles by this author; Krisoula H. Spatz , PharmD8xKrisoula H. SpatzSearch for articles by this author; Ira J. Dunkel , MD1,2xIra J. DunkelSearch for articles by this author; and Matthias A. Karajannis , MD, MS1,2xMatthias A. KarajannisSearch for articles by this author Show More 1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY2Department of Pediatrics, Weill Cornell Medical College, New York, NY3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY5Department of Ophthalmology and Neurology, Weill Cornell Medical College, New York, NY6Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY7Department of Orthopedics, Memorial Sloan Kettering Cancer Center, New York, NY8Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY https://doi.org/10.1200/PO.20.00444 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologySUPPORTInvestigational drug Debio1347 was provided by Debiopharm International SA under Single Patient Use protocols. This work was funded in part by the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and the National Cancer Institute Cancer Center Core Grant No. P30 CA008748.AUTHOR CONTRIBUTIONSConception and design: Sameer Farouk Sait, Krisoula H. Spatz, Ira J. Dunkel, Matthias A. KarajannisAdministrative support: Matthias A. KarajannisProvision of study materials or patients: Stephen W. Gilheeney, Daniel E. Prince, Ira J. Dunkel, Matthias A. KarajannisCollection and assembly of data: Sameer Farouk Sait, Stephen W. Gilheeney, Tejus A. Bale, Sofia Haque, Marc J. Dinkin, Stephanie Vitolano, Marc K. Rosenblum, Ira J. Dunkel, Matthias A. KarajannisData analysis and interpretation: Sameer Farouk Sait, Tejus A. Bale, Katarzyna Ibanez, Daniel E. Prince, Ira J. DunkelManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Sameer Farouk SaitConsulting or Advisory Role: AstraZenecaUncompensated Relationships: QED TherapeuticsSofia HaqueHonoraria: Advance MedicalConsulting or Advisory Role: Advance MedicalMarc J. DinkinEmployment: CareMount MedicalResearch Funding: Serenity TherapeuticsExpert Testimony: Medical Experts Nationwide, Ekblom & Partners LLPStephanie VitolanoStock and Other Ownership Interests: PfizerDaniel E. PrinceStock and Other Ownership Interests: Modernizing MedicineOpen Payments Link: https://openpaymentsdata.cms.gov/physician/289528Ira J. DunkelConsulting or Advisory Role: Apexigen, Celgene, Roche/Genentech, AstraZeneca, Fennec Pharma, Bristol Myers Squibb, QED Therapeutics, Day One TherapeuticsResearch Funding: Bristol Myers Squibb, Genentech, NovartisMatthias A. KarajannisStock and Other Ownership Interests: Johnson & Johnson (I)Consulting or Advisory Role: Bayer, Recursion Pharmaceuticals, QED Therapeutics, CereXis, AstraZenecaResearch Funding: NovartisTravel, Accommodations, Expenses: Bayer, Debiopharm GroupUncompensated Relationships: Debiopharm GroupOpen Payments Link: https://openpaymentsdata.cms.gov/physician/710370/summaryNo other potential conflicts of interest were reported.

Topics & Concepts